# US 8,278,276 B2 · Methods of treating autism

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,276 B2
- Document ID: US8278276B2
- Status: Granted
- Kind: B2
- Application number: 13/362,985
- Filed: 2012-01-31
- Published: 2012-05-24
- Granted: 2012-10-02
- Earliest claimed: 2006-11-22
- Assignees: Seaside Therapeutics, Inc.
- Inventors: Kathryn Roberts; Randall L. Carpenter; Mark F. Bear
- Web page: https://patentgrep.com/patent/US8278276B2

## CPC

- A61K 31/197: the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid (carnitine A61K31/205)
- A61K 31/195: having an amino group
- A61K 31/215: of carboxylic acids
- A61K 31/428: condensed with carbocyclic rings
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/22: Anxiolytics
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Subjects having autism are treated with a composition that includes gamma-aminobutyric acid agonists. The gamma-aminobutyric acid agonist (GABA) can be a GABA(B) agonist, such as baclofen.

## Claims

### Claim 1

A method of improving a social domain in a human having autism spectrum disorder, comprising the step of orally administering to the human a composition that includes a therapeutically effective amount of at least one gamma-aminobutyric acid agonist.

### Claim 2 (depends on 1)

The method of claim 1, wherein the gamma-aminobutyric acid (GABA) agonist administered to the human is a GABA(B) agonist.

### Claim 3 (depends on 2)

The method of claim 2, wherein the GABA(B) agonist includes baclofen.

### Claim 4 (depends on 3)

The method of claim 3, wherein baclofen is R-baclofen.

### Claim 5 (depends on 3)

The method of claim 3, wherein the baclofen is administered to the human in a dose of at least one member selected from the group consisting of about 2.5 mg, about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 40 mg, about 45 mg, about 50 mg and about 100 mg.

### Claim 6 (depends on 3)

The method of claim 3, wherein the baclofen is administered in a single daily dose.

### Claim 7 (depends on 3)

The method of claim 3, wherein the baclofen is administered to the human in multiple daily doses.

### Claim 8 (depends on 7)

The method of claim 7, wherein the baclofen is administered to the human in at least one member selected from the group consisting of two daily doses, three daily doses, four daily doses and five daily doses.

### Claim 9 (depends on 3)

The method of claim 3, wherein the R-baclofen administered to the human includes at least one member selected from the group consisting of about 85 mole percent R-baclofen, at least about 90 mole percent R-baclofen, at least about 95 mole percent R-baclofen and at least about 99 mole percent R-baclofen.

### Claim 10 (depends on 9)

The method of claim 9, wherein the baclofen administered to the human is at least about 99 mole percent R-baclofen.

### Claim 11 (depends on 1)

The method of claim 1, wherein the human further has fragile X syndrome.

### Claim 12 (depends on 1)

The method of claim 1, further including administering a Group I mGluR antagonist to the human.

### Claim 13 (depends on 12)

The method of claim 12, wherein the mGluR antagonist includes a mGluR5 antagonist.

### Claim 14 (depends on 12)

The method of claim 12, wherein the mGluR antagonist includes a mGluR1 antagonist.

### Claim 15 (depends on 1)

The method of claim 1, wherein administering the gamma-aminobutyric acid agonist to the human further causes a decrease in at least one member selected from the group consisting of an obsessive compulsive disorder, a sensory hyperarousal disorder, an anxiety disorder, a seizure disorder, irritability, aggression, startle tremor, repetitive/self-stimulatory behavior, eye diversion, hand biting, hitting of the head, and hitting of others.

### Claim 16 (depends on 1)

The method of claim 1, wherein the improvement in the social domain following administration of the gamma-aminobutyric acid agonist to the human includes an increase in at least one member selected from the group consisting of an appropriate response to spoken language, spontaneous attempts to interact, eye contact, motivation and calmness.

### Claim 17 (depends on 1)

The method of claim 1, wherein administration of the gamma-aminobutyric acid agonist to the human further improves a communication domain in the human.

### Claim 18 (depends on 17)

The method of claim 17, wherein the improvement in the communication domain includes an improvement in verbal language.

### Claim 19 (depends on 1)

The method of claim 1, wherein the improvement in the social domain following administration of the gamma-aminobutyric acid agonist to the human further includes an improvement in mood.

### Claim 20

A method of decreasing at least one member selected from the group consisting of irritability and aggression in a human having autism spectrum disorder, comprising the step of orally administering to the human a composition that includes a therapeutically effective amount at least one gamma-aminobutyric acid agonist.

### Claim 21 (depends on 20)

The method of claim 20, wherein the gamma-aminobutyric acid agonist is a GABA(B) agonist.

### Claim 22 (depends on 21)

The method of claim 21, wherein the GABA(B) agonist includes baclofen.

### Claim 23 (depends on 22)

The method of claim 22, wherein the baclofen is R-baclofen.

### Claim 24

A method of improving a social domain in a human having autism spectrum disorder, comprising the step of orally administering to the human a composition that includes a therapeutically effective amount of at least about 99 mole percent R-baclofen in the composition.

### Claim 25 (depends on 24)

The method of claim 24, wherein the human administered the composition further has an improvement in a communication domain.

### Claim 26

A method of improving a communication domain in a human having autism spectrum disorder, comprising the step of orally administering to the human a composition that includes a therapeutically effective amount of at least about 99 mole percent R-baclofen in the composition.
